Is Pretreatment With P2Y12 Inhibitors in Non-ST-Segment-Elevation Acute Coronary Syndrome Clinically Justified? Pretreatment With P2Y12 Inhibitors in Non-ST-Segment-Elevation Acute Coronary Syndrome Is Clinically Justified Response

被引：0
|
作者：
Collet, Jean-Philippe
Silvain, Johanne
Bellemain-Appaix, Anne
Montalescot, Gilles
机构：
来源：
CIRCULATION | 2014年 / 130卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1903 / 1903
页数：1
相关论文
共 50 条
  • [21] Selection and timing for invasive therapy in non-ST-segment-elevation acute coronary syndrome
    Meier, Pascal
    Froehlich, Georg M.
    Meller, Stephanie
    De Palma, Rodney
    Lansky, Alexandra J.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2013, 11 (04) : 437 - 445
  • [22] P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use
    Norgard, Nicholas B.
    DiNicolantonio, James J.
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2015, 6 (04) : 204 - 218
  • [23] Comparison of Oral P2Y12 Inhibitors in Acute Coronary Syndrome
    Ferracane, Elisa
    Bartoli, Laura
    Trippoli, Sabrina
    Messori, Andrea
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 135 : 183 - 184
  • [24] Choice of P2Y12 Inhibitors After Acute Coronary Syndrome
    Ando, Giuseppe
    Gragnano, Felice
    Pelliccia, Francesco
    Calabro, Paolo
    AMERICAN JOURNAL OF CARDIOLOGY, 2024, 211 : 377 - 377
  • [25] Coronary plaque rupture with subsequent thrombosis typifies the culprit lesion of non-ST-segment-elevation myocardial infarction, not unstable angina: non-ST-segment-elevation acute coronary syndrome study
    Sakaguchi, Mikumo
    Ehara, Shoichi
    Hasegawa, Takao
    Matsumoto, Kenji
    Nishimura, Satoshi
    Yoshikawa, Junichi
    Shimada, Kenei
    HEART AND VESSELS, 2017, 32 (03) : 241 - 251
  • [26] Effect of pretreatment with a P2Y12 inhibitor in patients with non-ST-elevation acute coronary syndrome: a systematic review and network meta-analysis
    Li, Yachao
    Lei, Mengjie
    Zhao, Zhigang
    Yang, Yanli
    An, Lei
    Wang, Jingyao
    Sun, Xue
    Li, Cairong
    Xue, Zengming
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10
  • [27] Do we need P2Y12 inhibitor pretreatment in non-ST elevation acute coronary syndrome? (vol 35, pg 319, 2016)
    De Caterina, Raffaele
    Veneri, Alessia Delli
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2016, 35 (11) : 635 - 635
  • [28] Coronary plaque rupture with subsequent thrombosis typifies the culprit lesion of non-ST-segment-elevation myocardial infarction, not unstable angina: non-ST-segment-elevation acute coronary syndrome study
    Mikumo Sakaguchi
    Shoichi Ehara
    Takao Hasegawa
    Kenji Matsumoto
    Satoshi Nishimura
    Junichi Yoshikawa
    Kenei Shimada
    Heart and Vessels, 2017, 32 : 241 - 251
  • [29] Pre-Treatment With Oral P2Y12 Inhibitors in Acute Coronary Syndromes Without ST-Segment Elevation The Saga Continues
    Capodanno, Davide
    Angiolillo, Dominick J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (08) : 915 - 918
  • [30] Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome?
    Christodoulidis, Georgios
    Baber, Usman
    Mehran, Roxana
    CURRENT OPINION IN CARDIOLOGY, 2014, 29 (04) : 301 - 306
12345